Last reviewed · How we verify
Zydis
At a glance
| Generic name | Zydis |
|---|---|
| Also known as | Zyprexa Zydis |
| Sponsor | Impel Pharmaceuticals |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week contr
Common side effects
Key clinical trials
- Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial (PHASE2)
- Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (PHASE1)
- Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer (PHASE2)
- Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas (PHASE1)
- Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (PHASE3)
- The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals (PHASE4)
- Olanzapine for Acute Headaches (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zydis CI brief — competitive landscape report
- Zydis updates RSS · CI watch RSS
- Impel Pharmaceuticals portfolio CI